NCT05382715View on ClinicalTrials.gov

A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis

TerminatedOBSERVATIONAL
Enrollment

175

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Colitis, Ulcerative
Interventions
DRUG

Ozanimod

Specified Dose on Specified Days

Trial Locations (1)

10825

Local Institution - 0001, Berlin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05382715 - A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis | Biotech Hunter | Biotech Hunter